Skip to main content
. 2015 Apr 6;2(4):382–394. doi: 10.18632/oncoscience.148

Figure 2. Anti-myeloma activity of pomalidomide on CD138+ cells from 3 MM patients.

Figure 2

CD138+ cells were selected and apoptosis with pomalidomide 1 μM for 24 h was evaluated with flow cytometry measurements. Annexin V+ /PI- cells were considered in early apoptosis phase. (A). Blue columns represent controls (11%,18%,3%); red columns represent % apoptosis after treatment with 23%, 33% and 26% annexin- V+ /PI-e cells (B). Data are presented as mean +/− SD. *P<0.05.